Volatile earnings with distant prospects of growth 

Sosei Offering: Company History, Earnings Structure, Business Model and Use of Proceeds

APAC IPOs & Placements

Zhen Zhou, Toh

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

Equity Capital Markets

<p><a href="https://www.smartkarma.com/entities/770" target="_blank" data-smartkarma-citation="entities:770:1">Sosei Group Corp (4565 JP)</a> is looking to raise US$204m by selling about 2m primary shares. Proceeds raised will be used to fund drug discovery and development.</p><p>The deal scores well on our framework owing to its good track record and strong price momentum recently. Since the acquisition of Heptares in 2015, the company has added more streams of revenues and pipeline development which eventually led to a sum of US$125m paid by Allergan last year. The deal size can be easily digested by the market…</p>

Sosei Group Corp (4565 JP) is looking to raise US$204m by selling about 2m primary shares. Proceeds raised will be used to fund drug discovery and development.The deal scores well on our framework owing to its good track record and strong price momentum recently. Since the acquisition of Heptares in 2015, the company has added more streams of revenues and pipeline development which eventually led to a sum of US$125m paid by Allergan last year. The deal size can be easily digested by the market…

Sosei Placement - One-Year Return for Its 2015 Equity Raise Was 354%